35,081 Shares in OmniAb, Inc. (NASDAQ:OABI) Bought by Atria Investments Inc

Atria Investments Inc bought a new position in shares of OmniAb, Inc. (NASDAQ:OABIFree Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 35,081 shares of the company’s stock, valued at approximately $148,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of OABI. Vanguard Group Inc. raised its holdings in OmniAb by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 5,713,539 shares of the company’s stock worth $30,967,000 after purchasing an additional 62,131 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in OmniAb by 13.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 26,843 shares of the company’s stock valued at $146,000 after acquiring an additional 3,108 shares during the last quarter. Janus Henderson Group PLC grew its holdings in OmniAb by 1.0% during the 1st quarter. Janus Henderson Group PLC now owns 7,859,438 shares of the company’s stock worth $42,598,000 after acquiring an additional 81,541 shares during the period. Simplicity Wealth LLC raised its position in shares of OmniAb by 23.3% in the 2nd quarter. Simplicity Wealth LLC now owns 42,160 shares of the company’s stock worth $158,000 after acquiring an additional 7,976 shares in the last quarter. Finally, Towerview LLC boosted its position in shares of OmniAb by 114.0% during the 2nd quarter. Towerview LLC now owns 535,000 shares of the company’s stock valued at $2,006,000 after purchasing an additional 285,000 shares in the last quarter. 72.08% of the stock is owned by institutional investors and hedge funds.

OmniAb Stock Up 1.8 %

Shares of OABI stock opened at $3.92 on Monday. The firm has a 50 day moving average of $4.14 and a 200-day moving average of $4.24. OmniAb, Inc. has a 52 week low of $3.56 and a 52 week high of $6.72. The company has a market cap of $553.58 million, a price-to-earnings ratio of -6.32 and a beta of -0.12.

Wall Street Analysts Forecast Growth

OABI has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th. Benchmark reaffirmed a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research report on Thursday, November 14th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 price objective on shares of OmniAb in a research report on Friday, August 16th.

Read Our Latest Analysis on OABI

OmniAb Profile

(Free Report)

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.

See Also

Want to see what other hedge funds are holding OABI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OmniAb, Inc. (NASDAQ:OABIFree Report).

Institutional Ownership by Quarter for OmniAb (NASDAQ:OABI)

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.